Gupta RK - Search Results

1

Virological Outcomes of Second-line Protease Inhibitor-Based Treatment for Human Immunodeficiency Virus Type 1 in a High-Prevalence Rural South African Setting: A Competing-Risks Prospective Cohort Analysis.

Collier D, Iwuji C, Derache A, de Oliveira T, Okesola N, Calmy A, Dabis F, Pillay D, Gupta RK; French National Agency for AIDS and Viral Hepatitis Research (ANRS) 12249 Treatment as Prevention (TasP) Study Group. Collier D, et al. Among authors: gupta rk. Clin Infect Dis. 2017 Apr 15;64(8):1006-1016. doi: 10.1093/cid/cix015. Clin Infect Dis. 2017. PMID: 28329393 Free PMC article.

2

HIV resistance and the developing world.

Gupta RK, Pillay D. Gupta RK, et al. Int J Antimicrob Agents. 2007 May;29(5):510-7. doi: 10.1016/j.ijantimicag.2007.01.003. Epub 2007 Mar 7. Int J Antimicrob Agents. 2007. PMID: 17346940 Review.

3

Emergence of drug resistance in HIV type 1-infected patients after receipt of first-line highly active antiretroviral therapy: a systematic review of clinical trials.

Gupta R, Hill A, Sawyer AW, Pillay D. Gupta R, et al. Clin Infect Dis. 2008 Sep 1;47(5):712-22. doi: 10.1086/590943. Clin Infect Dis. 2008. PMID: 18662137

4

Management of paediatric HIV-1 resistance.

Gupta RK, Gibb DM, Pillay D. Gupta RK, et al. Curr Opin Infect Dis. 2009 Jun;22(3):256-63. doi: 10.1097/qco.0b013e3283298f1f. Curr Opin Infect Dis. 2009. PMID: 19405216 Free PMC article. Review.

5

Mutation of a single residue renders human tetherin resistant to HIV-1 Vpu-mediated depletion.

Gupta RK, Hué S, Schaller T, Verschoor E, Pillay D, Towers GJ. Gupta RK, et al. PLoS Pathog. 2009 May;5(5):e1000443. doi: 10.1371/journal.ppat.1000443. Epub 2009 May 22. PLoS Pathog. 2009. PMID: 19461879 Free PMC article.

6

Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis.

Gupta RK, Hill A, Sawyer AW, Cozzi-Lepri A, von Wyl V, Yerly S, Lima VD, Günthard HF, Gilks C, Pillay D. Gupta RK, et al. Lancet Infect Dis. 2009 Jul;9(7):409-17. doi: 10.1016/S1473-3099(09)70136-7. Lancet Infect Dis. 2009. PMID: 19555900

7

Simian immunodeficiency virus envelope glycoprotein counteracts tetherin/BST-2/CD317 by intracellular sequestration.

Gupta RK, Mlcochova P, Pelchen-Matthews A, Petit SJ, Mattiuzzo G, Pillay D, Takeuchi Y, Marsh M, Towers GJ. Gupta RK, et al. Proc Natl Acad Sci U S A. 2009 Dec 8;106(49):20889-94. doi: 10.1073/pnas.0907075106. Epub 2009 Oct 28. Proc Natl Acad Sci U S A. 2009. PMID: 19864625 Free PMC article.

8

Causes and consequences of incomplete HIV RNA suppression in clinical trials.

Pozniak A, Gupta RK, Pillay D, Arribas J, Hill A. Pozniak A, et al. Among authors: gupta rk. HIV Clin Trials. 2009 Sep-Oct;10(5):289-98. doi: 10.1310/hct1005-289. HIV Clin Trials. 2009. PMID: 19906623 Review.

9

Drug resistance in human immunodeficiency virus type-1 infected Zambian children using adult fixed dose combination stavudine, lamivudine, and nevirapine.

Gupta RK, Ford D, Mulenga V, Walker AS, Kabamba D, Kalumbi M, Grant PR, Ferrier A, Pillay D, Gibb DM, Chintu C. Gupta RK, et al. Pediatr Infect Dis J. 2010 Aug;29(8):e57-62. doi: 10.1097/INF.0b013e3181e47609. Pediatr Infect Dis J. 2010. PMID: 20508547

10

Full-length HIV-1 Gag determines protease inhibitor susceptibility within in vitro assays.

Gupta RK, Kohli A, McCormick AL, Towers GJ, Pillay D, Parry CM. Gupta RK, et al. AIDS. 2010 Jul 17;24(11):1651-5. doi: 10.1097/qad.0b013e3283398216. AIDS. 2010. PMID: 20597164 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,816 results

Search Page

Filters